nach oben

Clinical Reviews in Allergy & Immunology

Erschienen in:

28.01.2022 | COVID-19 Zur Zeit gratis

Advanced Imaging Supports the Mechanistic Role of Autoimmunity and Plaque Rupture in COVID-19 Heart Involvement

verfasst von: Maria Elena Laino, Angela Ammirabile, Francesca Motta, Maria De Santis, Victor Savevski, Marco Francone, Arturo Chiti, Lorenzo Mannelli, Carlo Selmi, Lorenzo Monti

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

The cardiovascular system is frequently affected by coronavirus disease-19 (COVID-19), particularly in hospitalized cases, and these manifestations are associated with a worse prognosis. Most commonly, heart involvement is represented by myocarditis, myocardial infarction, and pulmonary embolism, while arrhythmias, heart valve damage, and pericarditis are less frequent. While the clinical suspicion is necessary for a prompt disease recognition, imaging allows the early detection of cardiovascular complications in patients with COVID-19. The combination of cardiothoracic approaches has been proposed for advanced imaging techniques, i.e., CT scan and MRI, for a simultaneous evaluation of cardiovascular structures, pulmonary arteries, and lung parenchyma. Several mechanisms have been proposed to explain the cardiovascular injury, and among these, it is established that the host immune system is responsible for the aberrant response characterizing severe COVID-19 and inducing organ-specific injury. We illustrate novel evidence to support the hypothesis that molecular mimicry may be the immunological mechanism for myocarditis in COVID-19. The present article provides a comprehensive review of the available evidence of the immune mechanisms of the COVID-19 cardiovascular injury and the imaging tools to be used in the diagnostic workup. As some of these techniques cannot be implemented for general screening of all cases, we critically discuss the need to maximize the sustainability and the specificity of the proposed tests while illustrating the findings of some paradigmatic cases.

Ghosh S, Deshwal H, Saeedan MB et al (2020) Imaging algorithm for COVID-19: a practical approach. Clin Imaging 72:22–30. https://doi.org/10.1016/j.clinimag.2020.11.022CrossRef

WHO Coronavirus (COVID-19) Dashboard | WHO coronavirus (COVID-19) dashboard with vaccination data. https://covid19.who.int/. Accessed 10 May 2021

Shi S, Qin M, Shen B et al (2020) Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 5:802–810. https://doi.org/10.1001/jamacardio.2020.0950CrossRef

Guo T, Fan Y, Chen M et al (2020) Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 5:811–818. https://doi.org/10.1001/jamacardio.2020.1017CrossRef

Nishiga M, Wang DW, Han Y et al (2020) COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol 17:543–558. https://doi.org/10.1038/s41569-020-0413-9CrossRef

Long B, Brady WJ, Koyfman A, Gottlieb M (2020) Cardiovascular complications in COVID-19. Am J Emerg Med 38:1504–1507. https://doi.org/10.1016/j.ajem.2020.04.048CrossRef

Stefanini GG, Chiarito M, Ferrante G et al (2020) Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. Heart 106:1512–1518. https://doi.org/10.1136/heartjnl-2020-317322CrossRef

Xu Z, Shi L, Wang Y et al (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8:420–422. https://doi.org/10.1016/S2213-2600(20)30076-XCrossRef

Zheng YY, Ma YT, Zhang JY, Xie X (2020) COVID-19 and the cardiovascular system. Nat Rev Cardiol. https://doi.org/10.1038/s41569-020-0360-5CrossRef

10.

Xiong T-Y, Redwood S, Prendergast B, Chen M (2020) Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J 41:1798–1800. https://doi.org/10.1093/eurheartj/ehaa231CrossRef

11.

Clerkin KJ, Fried JA, Raikhelkar J et al (2020) COVID-19 and cardiovascular disease. Circulation 141:1648–1655. https://doi.org/10.1161/CIRCULATIONAHA.120.046941CrossRef

12.

Adiguzel Y (2021) Molecular mimicry between SARS-CoV-2 and human proteins. Autoimmun Rev 20:102791. https://doi.org/10.1016/j.autrev.2021.102791CrossRef

13.

Yazdanpanah F, Hamblin MR, Rezaei N (2020) The immune system and COVID-19: friend or foe? Life Sci 256:117900. https://doi.org/10.1016/j.lfs.2020.117900CrossRef

14.

Akhmerov A, Marbán E (2020) COVID-19 and the heart. Circ Res 126:1443–1455. https://doi.org/10.1161/CIRCRESAHA.120.317055CrossRef

15.

Comini L, Pasini E, Bachetti T et al (2005) Acute haemodynamic effects of IL-6 treatment in vivo: involvement of vagus nerve in NO-mediated negative inotropism. Cytokine 30:236–242. https://doi.org/10.1016/j.cyto.2005.01.009CrossRef

16.

Mann DL (2015) Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res 116:1254–1268. https://doi.org/10.1161/CIRCRESAHA.116.302317CrossRef

17.

Magadum A, Kishore R (2020) Cardiovascular manifestations of COVID-19 infection. Cells. https://doi.org/10.3390/cells9112508CrossRef

18.

Unudurthi SD, Luthra P, Bose RJC et al (2020) Cardiac inflammation in COVID-19: lessons from heart failure. Life Sci 260:118482. https://doi.org/10.1016/j.lfs.2020.118482CrossRef

19.

Seta Y, Shan K, Bozkurt B et al (1996) Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 2:243–249. https://doi.org/10.1016/s1071-9164(96)80047-9CrossRef

20.

Generali E, Folci M, Selmi C, Riboldi P (2017) Immune-mediated heart disease. Adv Exp Med Biol 1003:145–171. https://doi.org/10.1007/978-3-319-57613-8_8CrossRef

21.

Novelli L, Motta F, De Santis M et al (2021) The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 - a systematic review of the literature. J Autoimmun 117:102592. https://doi.org/10.1016/j.jaut.2020.102592CrossRef

22.

Verdoni L, Mazza A, Gervasoni A et al (2020) An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 395:1771–1778. https://doi.org/10.1016/S0140-6736(20)31103-XCrossRef

23.

Consiglio CR, Cotugno N, Sardh F et al (2020) The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell 183:968-981.e7. https://doi.org/10.1016/j.cell.2020.09.016CrossRef

24.

Gruber CN, Patel RS, Trachtman R et al (2020) Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C). Cell 183:982-995.e14. https://doi.org/10.1016/j.cell.2020.09.034CrossRef

25.

Belhadjer Z, Méot M, Bajolle F et al (2020) Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic. Circulation 142:429–436. https://doi.org/10.1161/CIRCULATIONAHA.120.048360CrossRef

26.

Bajaj R, Sinclair HC, Patel K et al (2021) Delayed-onset myocarditis following COVID-19. Lancet Respir Med 9:e32–e34. https://doi.org/10.1016/S2213-2600(21)00085-0CrossRef

27.

Hoffmann M, Kleine-Weber H, Schroeder S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052CrossRef

28.

Siripanthong B, Nazarian S, Muser D et al (2020) Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm 17:1463–1471. https://doi.org/10.1016/j.hrthm.2020.05.001CrossRef

29.

Goulter AB, Goddard MJ, Allen JC, Clark KL (2004) ACE2 gene expression is up-regulated in the human failing heart. BMC Med 2:19. https://doi.org/10.1186/1741-7015-2-19CrossRef

30.

Basso C, Leone O, Rizzo S et al (2020) Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur Heart J 41:3827–3835. https://doi.org/10.1093/eurheartj/ehaa664CrossRef

31.

Pietsch H, Escher F, Aleshcheva G et al (2021) Proof of SARS-CoV-2 genomes in endomyocardial biopsy with latency after acute infection. Int J Infect Dis 102:70–72. https://doi.org/10.1016/j.ijid.2020.10.012CrossRef

32.

Jacobs W, Lammens M, Kerckhofs A et al (2020) Fatal lymphocytic cardiac damage in coronavirus disease 2019 (COVID-19): autopsy reveals a ferroptosis signature. ESC Heart Fail. https://doi.org/10.1002/ehf2.12958CrossRef

33.

Gauchotte G, Venard V, Segondy M et al (2021) SARS-Cov-2 fulminant myocarditis: an autopsy and histopathological case study. Int J Legal Med 135:577–581. https://doi.org/10.1007/s00414-020-02500-zCrossRef

34.

Kawakami R, Sakamoto A, Kawai K et al (2021) Pathological evidence for SARS-CoV-2 as a cause of myocarditis: JACC review topic of the week. J Am Coll Cardiol 77:314–325. https://doi.org/10.1016/j.jacc.2020.11.031CrossRef

35.

Puntmann VO, Carerj ML, Wieters I et al (2020) Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 5:1265–1273. https://doi.org/10.1001/jamacardio.2020.3557CrossRef

36.

Huang L, Zhao P, Tang D et al (2020) Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging. JACC Cardiovasc Imaging 13:2330–2339. https://doi.org/10.1016/j.jcmg.2020.05.004CrossRef

37.

Engelmann B, Massberg S (2013) Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 13:34–45. https://doi.org/10.1038/nri3345CrossRef

38.

Borges L, Pithon-Curi TC, Curi R, Hatanaka E (2020) COVID-19 and neutrophils: the relationship between hyperinflammation and neutrophil extracellular traps. Mediators Inflamm 2020:8829674. https://doi.org/10.1155/2020/8829674CrossRef

39.

Zuo Y, Yalavarthi S, Shi H et al (2020) Neutrophil extracellular traps in COVID-19. JCI Insight

40.

Blasco A, Coronado M-J, Hernández-Terciado F et al (2020) Assessment of neutrophil extracellular traps in coronary thrombus of a case series of patients with COVID-19 and myocardial infarction. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2020.7308CrossRef

41.

Abdel-Wahab N, Talathi S, Lopez-Olivo MA, Suarez-Almazor ME (2018) Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis. Lupus 27:572–583. https://doi.org/10.1177/0961203317731532CrossRef

42.

Xiao M, Zhang Y, Zhang S et al (2020) Antiphospholipid antibodies in critically ill patients with COVID-19. Arthritis Rheumatol 72:1998–2004. https://doi.org/10.1002/art.41425CrossRef

43.

Popovic B, Varlot J, Metzdorf PA et al (2021) Changes in characteristics and management among patients with ST-elevation myocardial infarction due to COVID-19 infection. Catheter Cardiovasc Interv 97:E319–E326. https://doi.org/10.1002/ccd.29114CrossRef

44.

Libby P, Loscalzo J, Ridker PM et al (2018) Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week. J Am Coll Cardiol 72:2071–2081. https://doi.org/10.1016/j.jacc.2018.08.1043CrossRef

45.

Tschöpe C, Sherif M, Anker MS et al (2021) COVID-19-convalescence phase unmasks a silent myocardial infarction due to coronary plaque rupture. ESC Heart Fail 8:971–973. https://doi.org/10.1002/ehf2.13186CrossRef

46.

Magro C, Mulvey JJ, Berlin D et al (2020) Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 220:1–13. https://doi.org/10.1016/j.trsl.2020.04.007CrossRef

47.

Blagova O, Varionchik N, Zaidenov V et al (2021) Anti-heart antibodies levels and their correlation with clinical symptoms and outcomes in patients with confirmed or suspected diagnosis COVID-19. Eur J Immunol 51:893–902. https://doi.org/10.1002/eji.202048930CrossRef

48.

Lucchese G, Flöel A (2020) Molecular mimicry between SARS-CoV-2 and respiratory pacemaker neurons. Autoimmun Rev 19:102556. https://doi.org/10.1016/j.autrev.2020.102556CrossRef

49.

Angileri F, Legare S, Marino Gammazza A et al (2020) Molecular mimicry may explain multi-organ damage in COVID-19. Autoimmun Rev 19:102591. https://doi.org/10.1016/j.autrev.2020.102591CrossRef

50.

Gil-Cruz C, Perez-Shibayama C, De Martin A et al (2019) Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy. Science 366:881–886. https://doi.org/10.1126/science.aav3487CrossRef

51.

Şelli ME, Thomas AC, Wraith DC, Newby AC (2017) A humanized HLA-DR4 mouse model for autoimmune myocarditis. J Mol Cell Cardiol 107:22–26. https://doi.org/10.1016/j.yjmcc.2017.04.003CrossRef

52.

Kaya Z, Katus HA, Rose NR (2010) Cardiac troponins and autoimmunity: their role in the pathogenesis of myocarditis and of heart failure. Clin Immunol 134:80–88. https://doi.org/10.1016/j.clim.2009.04.008CrossRef

53.

Revzin MV, Raza S, Srivastava NC et al (2020) Multisystem imaging manifestations of COVID-19, part 2: from cardiac complications to pediatric manifestations. Radiographics 40:1866–1892. https://doi.org/10.1148/rg.2020200195CrossRef

54.

Sandoval Y, Januzzi JL, Jaffe AS (2020) Cardiac troponin for assessment of myocardial injury in COVID-19: JACC review topic of the week. J Am Coll Cardiol 76:1244–1258. https://doi.org/10.1016/j.jacc.2020.06.068CrossRef

55.

Thygesen K, Alpert JS, Jaffe AS et al (2018) Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol 72:2231–2264. https://doi.org/10.1016/j.jacc.2018.08.1038CrossRef

56.

Capaccione KM, Leb JS, D’souza B et al (2020) Acute myocardial infarction secondary to COVID-19 infection: a case report and review of the literature. Clin Imaging 72:178–182. https://doi.org/10.1016/j.clinimag.2020.11.03CrossRef

57.

Citro R, Pontone G, Bellino M et al (2020) Role of multimodality imaging in evaluation of cardiovascular involvement in COVID-19. Trends Cardiovasc Med. https://doi.org/10.1016/j.tcm.2020.10.001CrossRef

58.

Galea N, Catapano F, Marchitelli L et al (2020) How to perform a cardio-thoracic magnetic resonance imaging in COVID-19: comprehensive assessment of heart, pulmonary arteries, and lung parenchyma. Eur Heart J Cardiovasc Imaging. https://doi.org/10.1093/ehjci/jeaa335CrossRef

59.

Galea N, Marchitelli L, Pambianchi G et al (2021) T2-mapping increase is the prevalent imaging biomarker of myocardial involvement in active COVID-19: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson 23:68. https://doi.org/10.1186/s12968-021-00764-xCrossRef

60.

Tavazzi G, Pellegrini C, Maurelli M et al (2020) Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail 22:911–915. https://doi.org/10.1002/ejhf.1828CrossRef

61.

Kelle S, Bucciarelli-Ducci C, Judd RM et al (2020) Society for Cardiovascular Magnetic Resonance (SCMR) recommended CMR protocols for scanning patients with active or convalescent phase COVID-19 infection. J Cardiovasc Magn Reson 22:61. https://doi.org/10.1186/s12968-020-00656-6CrossRef

62.

Kwee TC, Kwee RM (2020) Chest CT in COVID-19: what the radiologist needs to know. Radiographics 40:1848–1865. https://doi.org/10.1148/rg.2020200159CrossRef

63.

Pontone G, Baggiano A, Conte E et al (2020) “Quadruple rule-out” with computed tomography in a COVID-19 patient with equivocal acute coronary syndrome presentation. JACC Cardiovasc Imaging 13:1854–1856. https://doi.org/10.1016/j.jcmg.2020.04.012CrossRef

64.

Ferrante G, Fazzari F, Cozzi O et al (2020) Risk factors for myocardial injury and death in patients with COVID-19: insights from a cohort study with chest computed tomography. Cardiovasc Res 116:2239–2246. https://doi.org/10.1093/cvr/cvaa193CrossRef

65.

Nai Fovino L, Cademartiri F, Tarantini G (2020) Subclinical coronary artery disease in COVID-19 patients. Eur Heart J Cardiovasc Imaging 21:1055–1056. https://doi.org/10.1093/ehjci/jeaa202CrossRef

66.

Wu Q, Zhou L, Sun X et al (2017) Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci Rep 7:9110. https://doi.org/10.1038/s41598-017-09536-zCrossRef

67.

Rudski L, Januzzi JL, Rigolin VH et al (2020) Multimodality imaging in evaluation of cardiovascular complications in patients with COVID-19: JACC Scientific Expert Panel. J Am Coll Cardiol 76:1345–1357. https://doi.org/10.1016/j.jacc.2020.06.080CrossRef

68.

Liguori C, Farina D, Vaccher F et al (2020) Myocarditis: imaging up to date. Radiol Med 125:1124–1134. https://doi.org/10.1007/s11547-020-01279-8CrossRef

69.

Murphy WJ, Longo DL (2021) A possible role for anti-idiotype antibodies in SARS-CoV-2 infection and vaccination. N Engl J Med. https://doi.org/10.1056/NEJMcibr2113694CrossRef

70.

Paque RE, Miller R (1991) Autoanti-idiotypes exhibit mimicry of myocyte antigens in virus-induced myocarditis. J Virol 65:16–22. https://doi.org/10.1128/JVI.65.1.16-22.1991CrossRef

71.

Ghugre NR, Orbach A, Biswas L et al (2021) Suspected subclinical myocarditis detected by cardiac magnetic resonance imaging late post COVID-19 recovery. J Cardiol Cases 24:203–205. https://doi.org/10.1016/j.jccase.2021.04.014CrossRef

72.

Salerno M, Kwong RY (2020) CMR in the era of COVID-19: evaluation of myocarditis in the subacute phase. JACC Cardiovasc Imaging 13:2340–2342. https://doi.org/10.1016/j.jcmg.2020.06.013CrossRef

73.

Musher DM, Abers MS, Corrales-Medina VF (2019) Acute infection and myocardial infarction. N Engl J Med 380:171–176. https://doi.org/10.1056/NEJMra1808137CrossRef

74.

Smilowitz NR, Kunichoff D, Garshick M et al (2021) C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J 42:2270–2279. https://doi.org/10.1093/eurheartj/ehaa1103CrossRef

75.

Linde JJ, Kelbæk H, Hansen TF et al (2020) Coronary CT angiography in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol 75:453–463. https://doi.org/10.1016/j.jacc.2019.12.012CrossRef

76.

Stefanini GG, Montorfano M, Trabattoni D et al (2020) ST-elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes. Circulation 141:2113–2116. https://doi.org/10.1161/CIRCULATIONAHA.120.047525CrossRef

77.

Pontone G, Scafuri S, Mancini ME et al (2020) Role of computed tomography in COVID-19. J Cardiovasc Comput Tomogr. https://doi.org/10.1016/j.jcct.2020.08.013CrossRef

78.

Singh V, Choi AD, Leipsic J et al (2020) Use of cardiac CT amidst the COVID-19 pandemic and beyond: North American perspective. J Cardiovasc Comput Tomogr. https://doi.org/10.1016/j.jcct.2020.11.004CrossRef

79.

Zoghbi WA, DiCarli MF, Blankstein R et al (2020) Multimodality cardiovascular imaging in the midst of the COVID-19 pandemic: ramping up safely to a new normal. JACC Cardiovasc Imaging 13:1615–1626. https://doi.org/10.1016/j.jcmg.2020.06.001CrossRef

80.

Motwani M, Kidambi A, Greenwood JP, Plein S (2014) Advances in cardiovascular magnetic resonance in ischaemic heart disease and non-ischaemic cardiomyopathies. Heart 100:1722–1733. https://doi.org/10.1136/heartjnl-2013-304680CrossRef

81.

Zeng J-H, Liu Y-X, Yuan J et al (2020) First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection 48:773–777. https://doi.org/10.1007/s15010-020-01424-5CrossRef

82.

Alhogbani T (2016) Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. Ann Saudi Med 36:78–80. https://doi.org/10.5144/0256-4947.2016.78CrossRef

83.

Inciardi RM, Lupi L, Zaccone G et al (2020) Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol 5:819–824. https://doi.org/10.1001/jamacardio.2020.1096CrossRef

84.

Cuomo G, Menozzi M, Carli F et al (2020) Acute myocarditis as the main clinical manifestation of SARS-CoV 2 infection. Infect Dis Rep 12:8609. https://doi.org/10.4081/idr.2020.8609CrossRef

85.

Pirzada A, Mokhtar AT, Moeller AD (2020) COVID-19 and myocarditis: what do we know so far? CJC Open 2:278–285. https://doi.org/10.1016/j.cjco.2020.05.005CrossRef

86.

Han Y, Chen T, Bryant J et al (2020) Society for Cardiovascular Magnetic Resonance (SCMR) guidance for the practice of cardiovascular magnetic resonance during the COVID-19 pandemic. J Cardiovasc Magn Reson 22:26. https://doi.org/10.1186/s12968-020-00628-wCrossRef

87.

Friedrich MG, Sechtem U, Schulz-Menger J et al (2009) Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J Am Coll Cardiol 53:1475–1487. https://doi.org/10.1016/j.jacc.2009.02.007CrossRef

88.

Ferreira VM, Schulz-Menger J, Holmvang G et al (2018) Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 72:3158–3176. https://doi.org/10.1016/j.jacc.2018.09.072CrossRef

89.

Cundari G, Galea N, De Rubeis G et al (2021) Use of the new Lake Louise Criteria improves CMR detection of atypical forms of acute myocarditis. Int J Cardiovasc Imaging 37:1395–1404. https://doi.org/10.1007/s10554-020-02097-9CrossRef

90.

Turkbey EB, Nacif MS, Guo M et al (2015) Prevalence and correlates of myocardial scar in a US cohort. JAMA 314:1945–1954. https://doi.org/10.1001/jama.2015.14849CrossRef

91.

Ng M-Y, Ferreira VM, Leung ST et al (2020) Patients recovered from COVID-19 show ongoing subclinical myocarditis as revealed by cardiac magnetic resonance imaging. JACC Cardiovasc Imaging 13:2476–2478. https://doi.org/10.1016/j.jcmg.2020.08.012CrossRef

92.

Knight DS, Kotecha T, Razvi Y et al (2020) COVID-19: myocardial injury in survivors. Circulation 142:1120–1122. https://doi.org/10.1161/CIRCULATIONAHA.120.049252CrossRef

93.

Lagan J, Schmitt M, Miller CA (2018) Clinical applications of multi-parametric CMR in myocarditis and systemic inflammatory diseases. Int J Cardiovasc Imaging 34:35–54. https://doi.org/10.1007/s10554-017-1063-9CrossRef

94.

Cruz Rodriguez JB, Lange RA, Mukherjee D (2020) Gamut of cardiac manifestations and complications of COVID-19: a contemporary review. J Investig Med 68:1334–1340. https://doi.org/10.1136/jim-2020-001592CrossRef

95.

Revzin MV, Raza S, Warshawsky R et al (2020) Multisystem imaging manifestations of COVID-19, part 1: viral pathogenesis and pulmonary and vascular system complications. Radiographics 40:1574–1599. https://doi.org/10.1148/rg.2020200149CrossRef

96.

Suh YJ, Hong H, Ohana M et al (2021) Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis. Radiology 298:E70–E80. https://doi.org/10.1148/radiol.2020203557CrossRef

97.

Desborough MJR, Doyle AJ, Griffiths A et al (2020) Image-proven thromboembolism in patients with severe COVID-19 in a tertiary critical care unit in the United Kingdom. Thromb Res 193:1–4. https://doi.org/10.1016/j.thromres.2020.05.049CrossRef

98.

Contou D, Pajot O, Cally R et al (2020) Pulmonary embolism or thrombosis in ARDS COVID-19 patients: a French monocenter retrospective study. PLoS One 15:e0238413. https://doi.org/10.1371/journal.pone.0238413CrossRef

99.

Cattaneo M, Bertinato EM, Birocchi S et al (2020) Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thromb Haemost 120:1230–1232. https://doi.org/10.1055/s-0040-1712097CrossRef

100.

Kermani-Alghoraishi M, Ghahramani R (2021) A review of venous thromboembolism phenomena in COVID-19 patients. Curr Probl Cardiol 46:100692. https://doi.org/10.1016/j.cpcardiol.2020.100692CrossRef

101.

Visseren FL, Bouwman JJ, Bouter KP et al (2000) Procoagulant activity of endothelial cells after infection with respiratory viruses. Thromb Haemost 84:319–324CrossRef

102.

Ciceri F, Beretta L, Scandroglio AM et al (2020) Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc 22:95–97

103.

Moore AJE, Wachsmann J, Chamarthy MR et al (2018) Imaging of acute pulmonary embolism: an update. Cardiovasc Diagn Ther 8:225–243. https://doi.org/10.21037/cdt.2017.12.01

104.

van Dam LF, Kroft LJM, van der Wal LI et al (2020) Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: a different phenotype of thrombotic disease? Thromb Res 193:86–89. https://doi.org/10.1016/j.thromres.2020.06.010CrossRef

105.

Mueller-Peltzer K, Krauss T, Benndorf M et al (2020) Pulmonary artery thrombi are co-located with opacifications in SARS-CoV2 induced ARDS. Respir Med 172:106135. https://doi.org/10.1016/j.rmed.2020.106135CrossRef

106.

Vernuccio F, Lombardo FP, Cannella R et al (2020) Thromboembolic complications of COVID-19: the combined effect of a pro-coagulant pattern and an endothelial thrombo-inflammatory syndrome. Clin Radiol 75:804–810. https://doi.org/10.1016/j.crad.2020.07.019CrossRef

107.

Meinel FG, Nance JW, Schoepf UJ et al (2015) Predictive value of computed tomography in acute pulmonary embolism: systematic review and meta-analysis. Am J Med 128:747–59.e2. https://doi.org/10.1016/j.amjmed.2015.01.023CrossRef

108.

Ierardi AM, Angileri SA, Arrichiello A et al (2020) Pulmonary embolism in COVID-19: ventilation and perfusion computed tomography. IDCases 21:e00805. https://doi.org/10.1016/j.idcr.2020.e00805CrossRef

109.

Sharma M, Surani S (2020) Revisiting one of the dreaded outcomes of the current pandemic: pulmonary embolism in COVID-19. Medicina (Kaunas). https://doi.org/10.3390/medicina56120670CrossRef

110.

Zhang L, Yan X, Fan Q et al (2020) D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 18:1324–1329. https://doi.org/10.1111/jth.14859CrossRef

111.

Obi AT, Barnes GD, Wakefield TW et al (2020) Practical diagnosis and treatment of suspected venous thromboembolism during COVID-19 pandemic. J Vasc Surg Venous Lymphat Disord 8:526–534. https://doi.org/10.1016/j.jvsv.2020.04.009CrossRef

112.

Mestre-Gómez B, Lorente-Ramos RM, Rogado J et al (2021) Incidence of pulmonary embolism in non-critically ill COVID-19 patients. Predicting factors for a challenging diagnosis. J Thromb Thrombolysis 51:40–46. https://doi.org/10.1007/s11239-020-02190-9CrossRef

113.

Ventura-Díaz S, Quintana-Pérez JV, Gil-Boronat A et al (2020) A higher D-dimer threshold for predicting pulmonary embolism in patients with COVID-19: a retrospective study. Emerg Radiol 27:679–689. https://doi.org/10.1007/s10140-020-01859-1CrossRef

114.

Benito N, Filella D, Mateo J et al (2020) Pulmonary thrombosis or embolism in a large cohort of hospitalized patients with Covid-19. Front Med (Lausanne) 7:557. https://doi.org/10.3389/fmed.2020.00557CrossRef

115.

Taccone FS, Gevenois PA, Peluso L et al (2020) Higher intensity thromboprophylaxis regimens and pulmonary embolism in critically ill coronavirus disease 2019 patients. Crit Care Med 48:e1087–e1090. https://doi.org/10.1097/CCM.0000000000004548CrossRef

116.

Oudkerk M, Büller HR, Kuijpers D et al (2020) Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: report of the National Institute for Public Health of the Netherlands. Radiology 297:E216–E222. https://doi.org/10.1148/radiol.2020201629CrossRef

117.

Revel M-P, Parkar AP, Prosch H et al (2020) COVID-19 patients and the radiology department - advice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI). Eur Radiol 30:4903–4909. https://doi.org/10.1007/s00330-020-06865-yCrossRef

118.

Whyte MB, Kelly PA, Gonzalez E et al (2020) Pulmonary embolism in hospitalised patients with COVID-19. Thromb Res 195:95–99. https://doi.org/10.1016/j.thromres.2020.07.025CrossRef

119.

Fang C, Garzillo G, Batohi B et al (2020) Extent of pulmonary thromboembolic disease in patients with COVID-19 on CT: relationship with pulmonary parenchymal disease. Clin Radiol 75:780–788. https://doi.org/10.1016/j.crad.2020.07.002CrossRef

120.

Meiler S, Hamer OW, Schaible J et al (2020) Computed tomography characterization and outcome evaluation of COVID-19 pneumonia complicated by venous thromboembolism. PLoS One 15:e0242475. https://doi.org/10.1371/journal.pone.0242475CrossRef

121.

Birk R, Shaw D, Kennedy C et al (2020) Low detection rate of pulmonary embolism in patients presenting to the emergency department with suspected coronavirus disease 2019 (COVID-19): a single-centre UK study. Curr Probl Diagn Radiol. https://doi.org/10.1067/j.cpradiol.2020.09.014CrossRef

122.

Burger IA, Niemann T, Patriki D et al (2020) Is there a role for lung perfusion [99mTc]-MAA SPECT/CT to rule out pulmonary embolism in COVID-19 patients with contraindications for iodine contrast? Eur J Nucl Med Mol Imaging 47:2062–2063. https://doi.org/10.1007/s00259-020-04837-4CrossRef

123.

Lu Y, Macapinlac HA (2020) Perfusion SPECT/CT to diagnose pulmonary embolism during COVID-19 pandemic. Eur J Nucl Med Mol Imaging 47:2064–2065. https://doi.org/10.1007/s00259-020-04851-6CrossRef

Titel: Advanced Imaging Supports the Mechanistic Role of Autoimmunity and Plaque Rupture in COVID-19 Heart Involvement
verfasst von: Maria Elena Laino
Angela Ammirabile
Francesca Motta
Maria De Santis
Victor Savevski
Marco Francone
Arturo Chiti
Lorenzo Mannelli
Carlo Selmi
Lorenzo Monti
Publikationsdatum: 28.01.2022
Verlag: Springer US
Schlagwort: COVID-19
Erschienen in: Clinical Reviews in Allergy & Immunology / Ausgabe 1/2023
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-022-08925-1

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Advanced Imaging Supports the Mechanistic Role of Autoimmunity and Plaque Rupture in COVID-19 Heart Involvement

Abstract

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy

Identification of Parameters Representative of Immune Dysfunction in Patients with Severe and Fatal COVID-19 Infection: a Systematic Review and Meta-analysis

Das persistierende Post-COVID-Syndrom: Ursachen und Behandlungsstrategien

Public Health Measures and the Control of COVID-19 in China

Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO